BriaCell Therapeutics (TSX:BCT) ROCE % : -1,073.07% (As of Oct. 2024)

View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BriaCell Therapeutics's annualized ROCE % for the quarter that ended in Oct. 2024 was -1,073.07%.

BriaCell Therapeutics ROCE % Historical Data

The historical data trend for BriaCell Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics ROCE % Chart

BriaCell Therapeutics Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

ROCE %

Get a 7-Day Free Trial

-51.09

-55.16

-70.38

-291.81

BriaCell Therapeutics Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
ROCE %	Get a 7-Day Free Trial															-161.93	-299.46	-971.59	-	-1,073.07

BriaCell Therapeutics ROCE % Calculation

BriaCell Therapeutics's annualized ROCE % for the fiscal year that ended in Jul. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2024 )		(A: Jul. 2023 )		(A: Jul. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2024 )		(A: Jul. 2023 )		(A: Jul. 2024 )
	=	-45.709	/	( ( (35.886 - 2.379)	+	(8.053 - 10.232) )	/ 2 )
	=	-45.709	/	( (33.507	+	-2.179)	/ 2 )
	=	-45.709	/	15.664
	=	-291.81 %

BriaCell Therapeutics's ROCE % of for the quarter that ended in Oct. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	-28.356	/	( ( (8.053 - 10.232)	+	(14.327 - 6.863) )	/ 2 )
	=	-28.356	/	( ( -2.179	+	7.464 )	/ 2 )
	=	-28.356	/	2.6425
	=	-1,073.07 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2024) EBIT data.

BriaCell Therapeutics (TSX:BCT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BriaCell Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BCTX:USA 8BT0:Germany 8BT0:Germany

Address

235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Executives

Jamieson Bondarenko	Director
Marc Lustig	10% Security Holder, Director
Gadi Levin	Senior Officer
William Williams	Director, Senior Officer

BriaCell Therapeutics Headlines

No Headlines